Centre Testing Intl Group (300012) Report Interpretation

Overview

This earnings review argues that Centre Testing's 1H26 results demonstrate healthier growth rather than simply faster sales growth. Goldman Sachs sees organic growth, better margins in medical and consumer testing, semiconductor loss reduction, cash-flow discipline and overseas integration as supporting upgraded earnings forecasts and a maintained Buy rating.

Core views

Centre Testing reported 1H26 revenue, EBIT and net profit of Rmb3,429mn, Rmb598mn and Rmb564mn, up 16%, 24% and 21% year-on-year, respectively. Implied 2Q26 revenue, EBIT and net profit were Rmb1,935mn, Rmb424mn and Rmb385mn, up 16%, 19% and 16% year-on-year. These results were broadly in line with Goldman Sachs estimates: revenue was 1% below, EBIT 8% above and net profit 1% above. The firm highlights that around 10 percentage points of 1H26 revenue growth was organic and around 6 percentage points came from M&A consolidation, consistent with management's preferred long-term balance of roughly two-thirds organic growth. Operating cash flow rose 150% year-on-year to Rmb438mn, while overseas revenue rose 63% and exceeded 10% of group sales. The central conclusion is that the mix of growth has improved. Management is prioritizing revenue quality, collections, cash conversion and margin resilience, including exiting government-sampling and construction work with unattractive pricing or collection terms. At the group level, 2Q26 gross margin, EBIT margin and net-profit margin were 52%, 22% and 20%, respectively—2 percentage points, 2 percentage points and flat versus Goldman Sachs estimates. Margin pressure in life sciences, industrial products and international trade was largely attributable to acquisition, category or timing mix rather than weaker core operations, while medical and consumer testing supplied stronger operating leverage. Medical is the clearest profitability inflection. Its 1H26 and 2Q26 revenue grew 57% and 58% year-on-year, respectively, and 1H26 gross margin rose 9.1 percentage points to 28%, with 2Q26 gross margin at 52%. The segment was profitable for three consecutive months from May through July after losses in the first four months. Goldman Sachs cites strong CRO orders from China's innovative-drug recovery and license-out demand, plus capacity constraints: CRO facilities and Kunshan passive medical-device capacity are close to full, pre-clinical safety-assessment orders are booked into early 2027, and an approved Kunshan Phase II investment of around Rmb100mn could nearly double relevant medical-device and pre-clinical capacity. The monkey-farm acquisition is described as a supply and cost advantage, with management targeting more than 50% self-supply of monkeys within three years, rather than an asset-revaluation driver. Consumer Goods delivered fully organic 1H26 growth of 13%, with 2Q26 growth of 11%; its share of group revenue was 17% in both periods. Gross margin improved by 5.4 percentage points year-on-year to 47% in 1H26 and reached 48% in 2Q26. Export demand supported electronics, textiles, light industry and toys, while electrification, autonomous driving, automotive EMC and connected-vehicle demand continued to support auto testing. Management highlighted high incremental profit contribution from textiles, toys, light industry and auto electronics, which implies gross profit can rise faster than revenue as utilization increases. Semiconductor revenue was subdued because lower-margin hardware and socket revenue declined and some hardware revenue was not yet recognized, but testing-service revenue grew strongly, raising gross margin and producing a large loss reduction. Management expects further improvement as FAMA-related equipment arrives, although it has not confirmed breakeven timing. Life Science grew 12% in 1H26 and 14% in 2Q26, representing 42% and 44% of group revenue, but 1H26 gross margin declined 1.3 percentage points to 50%. Environmental revenue recognition lagged order intake because of sampling and weather constraints, though management said efficiency measures and customer/project selection improved environmental margins. Food testing benefited from pet food, enterprise customers, overseas platforms and the Singapore acquisition of Ugene. Acquired food assets, including SafetySA's food business, dilute near-term margins, but management expects improvement through chemical and hazardous-substance testing capabilities, centralized procurement, IT integration, lean management and analytics. Industrial Products grew 19% in 1H26 and 17% in 2Q26, but its organic growth was only about 5-6% because the company is leaving low-quality construction work. Gross margin fell 1.5 percentage points year-on-year to 42% in 1H26, mainly from the lower-margin SafetySA and Emicert acquisitions, Emicert's revenue-recognition seasonality and Middle East disruption affecting maritime and shipping. Goldman Sachs emphasizes that materials testing is the stronger sub-line, with rapid growth, already high margins and rising profitability. Longer term, management expects materials testing, HSEQ, calibration, sustainability/certification and other higher-value services to matter more than construction-cycle exposure. International Trade remained structurally high-margin, with 1H26/2Q26 revenue growth of 13%/9% and gross margins of 72%/79%; the 1H26 margin decline of 1.6 percentage points reflected faster growth in lower-margin audit and inspection versus chemical and reliability testing, not weaker acquired-asset quality. For the second half, management expects medical and consumer testing to be the main drivers of full-year gross-margin improvement. Semiconductor profitability should improve with service scale and selective hardware recognition, while acquired-asset margin recovery is a multi-period process rather than an immediate reset. Capital expenditure is expected to move toward 10% of revenue from 7%, excluding base construction, directed toward semiconductors, medical, medical devices, NEV/autonomous driving, the low-altitude economy and robotics. With Chengdu and Shenzhen Phase II base construction largely completed, management expects less property-heavy investment that dilutes ROE and more productive laboratory capacity. Internationalization is another growth lever. SafetySA, Emicert and Openview integration is progressing, while Ugene is intended as a Southeast Asia food-testing platform. Management sees Emicert's EU ETS and future CBAM credentials as relevant to Chinese exporters, citing more than 2,000 potential exporters and potentially broader demand after 2028 as CBAM extends downstream. M&A priorities include consumer goods, food, maritime and certification, especially certification agencies in Europe, South America and potentially the US, while management stresses strategic fit and valuation discipline rather than transaction volume. AI has progressed to more than 120 application scenarios; management sees near-term benefits in efficiency, round-the-clock service, opportunity capture and analytical accuracy, while fully automated laboratories remain a longer-term objective. Goldman Sachs adjusts 2026E-30E revenue estimates by about 1% but raises net-income forecasts by about 3-5%, reflecting medical's profitability inflection, consumer margin expansion, semiconductor loss reduction and better operating and cash-flow discipline despite near-term M&A mix dilution. The 12-month target price rises 5.1% to Rmb18.60 from Rmb17.70, based on 21x 2027E P/E, and the firm maintains Buy. Its longer-term thesis is that CTI's laboratory network, service quality, cost structure, flexibility and consolidation potential in China's fragmented TIC market can support 2026-30E revenue and net-profit CAGRs of 12% and 16%, respectively, against its estimated 7% long-term CAGR for China's TIC market.

Analysis framework

Goldman Sachs first compares reported 1H26 and implied 2Q26 financials with its estimates, then evaluates the organic-versus-M&A growth mix, segment revenue and margin trends, and cash conversion. It uses management commentary to assess operating leverage, acquisition integration, capacity additions, capital allocation and overseas expansion, before revising earnings forecasts and applying a 2027E P/E multiple to set its target price.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Forward P/E target-price valuation

  The 12-month Rmb18.60 target price is based on a 21x 2027E P/E multiple.

• Industry AnalysisVolume-price decomposition

  Organic versus M&A revenue growth and segment margin-mix analysis

  The report separates organic growth from M&A consolidation and explains group profitability through segment mix, service mix and margin changes.

• Corporate Fundamentals and FinanceFree cash flow analysis

  Operating cash flow and capital-allocation assessment

  The report uses the 150% increase in operating cash flow, receivables discipline and capex direction to support its view of improving revenue quality and cash conversion.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Centre Testing Intl Group (300012.SZ)

  Primary covered company; Goldman Sachs maintains Buy as it expects a higher-quality growth mix to support earnings upgrades.

  Strengths

  Organic growth, medical profitability inflection, consumer margin expansion, semiconductor loss reduction, rising overseas revenue and improved operating cash flow.

  Weaknesses

  Near-term margin dilution from acquired assets, low-margin hardware mix and uneven revenue-recognition timing in some segments.

  Comparison

  Goldman Sachs considers operational performance more resilient than comparable peers, citing continued market-share gains and consistent margins.

  Risks

  Credibility damage, intensifying pricing competition, receivables risk from the 3rd National Soil Census and acquisition-related impairment.

Key data

• 1H26 revenueRmb3,429mn+16% year-on-year; around 10 percentage points organic growth and 6 percentage points from M&A consolidation.
• 1H26 EBIT / net profitRmb598mn / Rmb564mn+24% / +21% year-on-year.
• Implied 2Q26 revenue / EBIT / net profitRmb1,935mn / Rmb424mn / Rmb385mn+16% / +19% / +16% year-on-year; -1% / +8% / +1% versus Goldman Sachs estimates.
• 2Q26 margins52% gross margin / 22% EBIT margin / 20% net-profit margin+2pp / +2pp / 0pp versus Goldman Sachs estimates.
• 1H26 operating cash flowRmb438mn+150% year-on-year.
• Overseas revenue>10% of group revenue+63% year-on-year in 1H26.
• Medical segment growth+57% 1H26 revenue; +58% 2Q26 revenueProfitable in May, June and July after losses in the first four months.
• Forecast revisionsRevenue estimates adjusted by c.1%; net income estimates raised c.3-5% for 2026E-30EDriven by improved growth quality, medical, consumer testing, semiconductors and cash-flow discipline.
• Target priceRmb18.60Raised from Rmb17.70; based on 21x 2027E P/E; 22.2% upside versus Rmb15.22.

Impact & implications

The report argues that CTI's earnings profile is improving because higher-margin medical and consumer services, semiconductor testing-service scale and stronger cash discipline outweigh near-term dilution from acquisitions and lower-margin activity. It expects the growth mix to become less dependent on low-quality construction and sampling projects and more exposed to specialized testing, overseas expansion and productive laboratory capacity.

Risks

• Damage to the company's credibility.
• Intensifying pricing competition.
• Greater accounts-receivable risk from the 3rd National Soil Census.
• Potential impairment arising from acquisitive growth.

What to watch

• Whether medical and consumer testing remain the main drivers of full-year gross-margin improvement.
• The pace of semiconductor testing-service scale-up and confirmation of breakeven timing.
• Margin recovery at SafetySA and Emicert as integration advances.
• Overseas revenue growth and integration of SafetySA, Emicert, Openview and Ugene.
• The mix and returns of capex as spending moves toward about 10% of revenue.
• Execution of higher-value industrial testing and selective M&A strategy.